Wall Street brokerages expect that Conatus Pharmaceuticals Inc (NASDAQ:CNAT) will announce sales of $9.70 million for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Conatus Pharmaceuticals’ earnings, with estimates ranging from $7.95 million to $11.75 million. Conatus Pharmaceuticals reported sales of $9.57 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 1.4%. The business is expected to announce its next earnings results on Wednesday, November 7th.

On average, analysts expect that Conatus Pharmaceuticals will report full-year sales of $36.86 million for the current financial year, with estimates ranging from $32.59 million to $38.51 million. For the next financial year, analysts forecast that the company will report sales of $46.27 million, with estimates ranging from $27.65 million to $75.44 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Conatus Pharmaceuticals.

Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its earnings results on Friday, August 3rd. The biotechnology company reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.05. The company had revenue of $8.77 million during the quarter, compared to analysts’ expectations of $9.06 million. Conatus Pharmaceuticals had a negative net margin of 48.46% and a negative return on equity of 69.68%.

A number of research analysts have issued reports on the stock. Zacks Investment Research raised shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 4th. ValuEngine cut shares of Conatus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, October 4th. Finally, Oppenheimer set a $14.00 price target on shares of Conatus Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 1st. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $11.80.

Several large investors have recently added to or reduced their stakes in the company. Jane Street Group LLC bought a new stake in Conatus Pharmaceuticals during the 2nd quarter worth approximately $142,000. Paloma Partners Management Co purchased a new position in Conatus Pharmaceuticals in the second quarter valued at approximately $547,000. Bank of America Corp DE lifted its stake in Conatus Pharmaceuticals by 75.7% in the second quarter. Bank of America Corp DE now owns 140,687 shares of the biotechnology company’s stock valued at $602,000 after purchasing an additional 60,604 shares during the last quarter. Alambic Investment Management L.P. lifted its stake in Conatus Pharmaceuticals by 207.0% in the second quarter. Alambic Investment Management L.P. now owns 264,665 shares of the biotechnology company’s stock valued at $1,133,000 after purchasing an additional 178,461 shares during the last quarter. Finally, MYDA Advisors LLC purchased a new position in Conatus Pharmaceuticals in the second quarter valued at approximately $154,000. Hedge funds and other institutional investors own 33.50% of the company’s stock.

Shares of NASDAQ CNAT traded up $0.11 during midday trading on Friday, reaching $4.77. The company had a trading volume of 383,900 shares, compared to its average volume of 608,523. The stock has a market cap of $155.55 million, a P/E ratio of -7.87 and a beta of 1.38. Conatus Pharmaceuticals has a 1 year low of $3.22 and a 1 year high of $7.95. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 0.68.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

See Also: Risk Tolerance

Get a free copy of the Zacks research report on Conatus Pharmaceuticals (CNAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.